No Data
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and
Ocugen Announces CSO to Present on Modifier Gene Therapy At International Society for Cell & Gene Therapy 2024
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cel
DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were slightly lower this morning, with the Dow futures falling around 10 points on Friday.Shares of DXC Technology Company (NYSE:DXC) fell sharply in today's pre-market trading afte
Nayax Posts Weak Q1 Results, Joins GameStop, Iris Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Thursday.Shares of Nayax Ltd. (NASDAQ:NYAX) fell sharply in today's pre-market trading following weak
Ocugen Is Maintained at Buy by Chardan Capital
Ocugen Is Maintained at Buy by Chardan Capital
Ocugen Price Target Maintained With a $5.00/Share by Chardan Capital
Ocugen Price Target Maintained With a $5.00/Share by Chardan Capital